Recent Updates
Recently added Catalysts
MLTX Negative Sentiment Score: 20/100

MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

Key Takeaway: MoonLake Immunotherapeutics is embroiled in a class action lawsuit which alleges violations of securities laws due to misleading statements regarding its drug sonelokimab. The lawsuit highlights that the company claimed its drug outperformed competitors without backing those claims with proven advantages. Following the disastrous results from a Phase 3 trial, the credibility of the company’s public statements has come under scrutiny. Shareholders affected by the alleged misinformation are encouraged to contact the DJS Law Group for participation in the legal proceedings.

Market Sentiment Analysis

CONCERNS & RISKS

  • MoonLake Immunotherapeutics is facing a class action lawsuit for securities law violations.
  • The complaint alleges that the company made false and misleading statements about its drug, sonelokimab.
  • The Phase 3 trial results were deemed disastrous by analysts, undermining the company's claims.

Full Press Release Details

LOS ANGELES, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 10, 2024 to September 29, 2025
DEADLINE: December 15, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. MoonLake claimed its sonelokimab (SLK) drug was superior to competing therapies without any proven advantages. When the Company released the results of its Phase 3 trial, analysts labeled them “disastrous.” Based on these facts, MoonLake’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What lawsuit is DJS Law Group involved in?

DJS Law Group is handling a class action lawsuit against MoonLake Immunotherapeutics for misleading statements related to its drug sonelokimab.

What is the class period for this lawsuit?

The class period for the lawsuit runs from March 10, 2024, to September 29, 2025.

What is the deadline to join the lawsuit?

The deadline for shareholders to join the lawsuit is December 15, 2025.

Do I need to be a lead plaintiff to participate?

No, becoming a lead plaintiff is not necessary to participate in recovery.

What services does DJS Law Group offer?

DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals.

Last updated: Dec 5, 2025